Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. Uppsala Monitoring Centre strives to meet a global need for better communication practices in our field. Our communication activities focus on raising awareness of UMC’s work, the importance of pharmacovigilance, and the basics of how adverse drug reactions occur and should be handled.

  2. Identifying safety signals. Signal work aims to identify and describe suspected harm to patients caused by the medicines they use. The evidence comes primarily in the form of spontaneous reports from health professionals across the world, from pharmaceutical companies, and some from patients. Signal work is a core UMC activity.

  3. Uppsala Monitoring Centre. Cursos en ingles. Causality assessment of case series Learning objective: To understand the important elements to consider when assessing ...

  4. Uppsala Monitoring Centre is an independent, non-profit foundation and a centre for international service and scientific research in the field of pharmacovigilance. We advance the safety of patients by exploring and understanding the risks and benefits of medicines, with the ultimate aim of helping patients and physicians make wise therapeutic decisions.

  5. 22 de feb. de 2024 · Uppsala Reports is the news magazine for anyone interested in the latest issues in medicines safety. Country updates, tools and technology, exciting new research – we’ve been collecting stories from UMC and the WHO Programme for International Drug Monitoring since 1996. Printed copies of the magazine are shipped to member countries in the ...

  6. Uppsala Monitoring Centre. English courses. Causality assessment of case series Learning objective: To understand the important elements to consider when assessing ...

  7. who-umc.org › idmpIDMP | UMC

    UMC, as the WHO Collaborating Centre for International Drug Monitoring, is developing processes and systems to support Pharmaceutical Product Identifiers (PhPID, ISO 11616). The role of generating and maintaining unique global PhPID identifiers will require specialist expertise in handling global drug information, working collaboratively with key stakeholders around the world.